Skip to search formSkip to main contentSkip to account menu

Sarcoma Differentiation Score 1

Known as: FNCLCC Sarcoma Grade 1, Sarcoma FNCLCC Grade 1 
National Institutes of Health

Related topics

Related topics

5 relations
Connective and Soft TissueEpithelial CellsEpitheliumNeoplastic Cell

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Traitement préopératoire des adénocarcinomes oesogastriques
Gastric and esophageal adenocarcinomas (GEA) are among the leading causes of cancer-related death worldwide. Despite a decline in… 
2011
2011
Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal…
TPS178 Background: Advanced gastroesophageal cancers (AGEC) harbour a dismal prognosis (overall survival [OS] < 1 year). EGFR… 
2009
2009
Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.
Objective: To evaluate the combined administration of Docetaxel (D) and Epirubicin (E) versus FEC 100 on 5-year disease-free… 
Review
2008
Review
2008
Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques
RésuméMalgréde récents progrés dans la prise en charge des adénocarcinomes œsogastriques (AOG), leur mortalitéreste élevée et… 
2006
2006
A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04…
7057 Background: This study aimed at determining whether or not thalidomide prolongs survival of patients (pts) suffering from… 
2006
2006
Preliminary results of a randomized phase III trial comparing streptozotocin plus fluorouracil versus interferon for metastatic carcinoid tumors (FNCLCC - FFCD 9710).
4090 Background: Streptozotocin and 5 FU in combination is widely used for the treatment of advanced carcinoids tumors… 
2004
2004
Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma. Results at 18 months (FNCLCC-GORTEC).
5504 Background: Between November 1997 and March 2002, 171 following patients were enrolled in this phase III multicenter trial… 
2004
2004
Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma. 24 months results (FNCLCC-GORTEC)
Review
1999
Review
1999
[INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].
BACKGROUND Almost 10% of breast and ovarian cancer are inherited, and the majority are linked to BRCA1 and BRCA2 germline… 
Review
1998
Review
1998
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight…
BACKGROUND Almost 10% of breast and ovarian cancer are inherited, and the majority are linked to BRCA1 and BRCA2 germline… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)